Effect of Sarcopenia on 10-Year Risk of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
DOI: https://doi.org/10.2147/dmso.s450225
2024-04-09
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Long-Fei Xia, 1 Jing-Bo Li, 2 Guo-Sheng Tian, 2 Wei-Ran Jiang, 3 Yao-Shuang Li, 1 Chen-Ying Lin, 1 Hui-Na Qiu, 2 Fan Wu, 4 Jun-Jia Wang, 5 Chun-Jun Li, 2 Jing-Na Lin 2 1 Tianjin Union Medical Center, Tianjin Medical University, Tianjin, 300070, People's Republic of China; 2 Department of Endocrinology, Health Management Center, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin, 300121, People's Republic of China; 3 Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA; 4 School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China; 5 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China Correspondence: Jing-Na Lin; Chun-Jun Li, Email ; Objective: To investigate the impact of sarcopenia on the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among individuals with type 2 diabetes mellitus (T2DM). Methods: This study included the clinical, laboratory, and body composition data of 1491 patients with T2DM who were admitted to the Department of Endocrinology and Metabolism at Tianjin Union Medical Center from July 2018 to July 2023. The China-PAR model was utilized to evaluate cardiovascular disease risk. Associations between ASCVD risk and various clinical parameters were analyzed, and the relationship between body composition parameters and ASCVD risk was assessed using logistic regression. Results: The analysis revealed that T2DM patients with sarcopenia had a higher 10-year ASCVD risk compared to those without sarcopenia, with reduced muscle mass independently predicting an increased risk of cardiovascular disease. This association was significant among female T2DM patients, while male T2DM patients with sarcopenia showed a marginally higher median ASCVD risk compared to their non-sarcopenic counterparts. ASCVD risk inversely correlated with body muscle parameters and positively correlated with fat content parameters. Specifically, height- and weight-adjusted fat mass (FM, FM%, FMI) were identified as risk factors for ASCVD. Conversely, muscle parameters adjusted for weight and fat (ASM%, SMM%, FFM%, ASM/FM, SMM/FM, FMM/FM) were protective against ASCVD risk. These findings highlight the critical role of sarcopenia in influencing cardiovascular disease risk among Chinese patients with T2DM, as predicted by the China-PAR model. Conclusion: This study highlights the importance of sarcopenia in T2DM patients, not only as an indicator of ASCVD risk, but possibly as an independent risk factor in this demographics. Keywords: atherosclerotic cardiovascular disease, ASCVD, type 2 diabetes, T2DM, sarcopenia, fat content, muscle mass Sarcopenia is a disease characterized by the gradual decrease of muscle function, mass, and strength. It is linked to a higher risk of hospitalization, disability, falls, death, and loss of self-care ability. 1 Sarcopenia was first described by Irwin Rosenberg in 1988 as an age-related decline in skeletal muscle function and mass. 2 Baumgartner further provided a method to assess sarcopenia using height-adjusted appendicular lean mass (kg/m 2 ). 3 From a physiological perspective, beyond 40 years of age, there is a progressive and systemic loss of muscle mass; before the age of 70, this degradation rate is estimated to be 8% per decade and subsequently 15–25% per decade. 4 Depending on different demographic characteristics and assessment criteria, sarcopenia is present in 10% to 40% of people worldwide. 5 Over the past decade, sarcopenia has received increasing attention, particularly with the gradual increase in the world's life expectancy. Over the next 30 years, there is a projected considerable increase in the prevalence of sarcopenia. 6 Sarcopenia will affect more than 200 million elderly individuals with worldwide, 6 which raises serious concerns for public health. Type 2 diabetes mellitus (T2DM) is one of the most serious and pressing health issues in the world. According to predictions from the International Diabetes Federation, the prevalence of T2DM among adults aged 20 to 79 will rise from 9.3% in 2019 to 10.2% by 2030. Specifically, there will be 578 million T2DM patients by 2030 compared to 463 million in 2019. It is projected that diabetes-related healthcare costs worldwide total 727 billion US dollars. 7 With population aging and a rise in the incidence of metabolic and musculoskeletal diseases, changes in body composition occur during the aging process, leading to an considerable dec -Abstract Truncated-
endocrinology & metabolism